CytomX Therapeutics (CTMX) Free Cash Flow (2016 - 2025)
Historic Free Cash Flow for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$15.4 million.
- CytomX Therapeutics' Free Cash Flow rose 2567.48% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.4 million, marking a year-over-year increase of 1850.71%. This contributed to the annual value of -$86.5 million for FY2024, which is 5216.0% down from last year.
- Latest data reveals that CytomX Therapeutics reported Free Cash Flow of -$15.4 million as of Q3 2025, which was up 2567.48% from -$15.8 million recorded in Q2 2025.
- CytomX Therapeutics' Free Cash Flow's 5-year high stood at $9.3 million during Q1 2023, with a 5-year trough of -$42.0 million in Q1 2022.
- In the last 5 years, CytomX Therapeutics' Free Cash Flow had a median value of -$22.2 million in 2023 and averaged -$22.6 million.
- Data for CytomX Therapeutics' Free Cash Flow shows a peak YoY increase of 12211.94% (in 2023) and a maximum YoY decrease of 131136.51% (in 2023) over the last 5 years.
- Over the past 5 years, CytomX Therapeutics' Free Cash Flow (Quarter) stood at -$31.4 million in 2021, then surged by 94.99% to -$1.6 million in 2022, then plummeted by 1311.37% to -$22.2 million in 2023, then increased by 10.08% to -$20.0 million in 2024, then increased by 22.85% to -$15.4 million in 2025.
- Its Free Cash Flow was -$15.4 million in Q3 2025, compared to -$15.8 million in Q2 2025 and -$21.2 million in Q1 2025.